EDCTP at AIDS 2024

22 Jul 2024 08:00 - 26 Jul 2024 17:00
Munich, Germany & virtual
Type of event International meeting

The 25th International AIDS Conference – AIDS 2024 – will take place in Munich, Germany, and virtually from 22 to 26 July 2024. AIDS 2024 will convene thousands of people living with, affected by, and working on HIV to share knowledge, best practices and lessons learned from the HIV response over the past 40 years, as well as from the responses to COVID-19, mpox and other public health threats.

Dr Johanna Schaefer, Project Officer, will represent EDCTP at AIDS 2024. Additionally, several grantees supported by EDCTP2 and Global Health EDCTP3 will present their work. Below is an overview and visit the AIDS 2024 programme page for more information.

Oral abstract sessions

  • OAC08
    Final vaccine efficacy results from PrEPVacc: A phase IIb HIV prophylactic vaccine trial of two active regimens each compared to placebo
    Eugene Ruzagira | EDCTP2 project: PrEPVacc
    23 July 2024 | 16:30-17:30 | Hall B0a/Channel 4
  • OAB21
    Randomised placebo-controlled trial of high-dose Vitamin D and low-dose calcium supplementation to improve bone density in adolescents with perinatally-acquired HIV in Southern Africa
    Rashida Ferrand | EDCTP2 project: VITALITY
    25 July 2024 | 10.30-11.30 | Room 14b/Channel 3
  • OAC22
    Differences in risk factors between high and low vertical HIV transmission settings: Implications for elimination of pediatric HIV
    Kira Elsbernd | EDCTP2 project: LIFE
    25 July 2024 | 10:30-11:30 | Hall B0a/Channel 4
  • OAB26
    PedMAb1 clinical trial: Safety assessment of CAP256V2LS and VRC07-523LS to prevent breastmilk HIV transmission in HIV-1 exposed and negative neonates
    Gabriella Scarlatti | EDCTP2 project: PedMAB
    25 July 2024 | 15:00-16:00 | Hall B0b/Channel 5

Poster presentations

  • Differences in risk factors between high and low vertical HIV transmission settings: Implications for elimination of pediatric HIV
    Kira Elsbernd | EDCTP2 project: LIFE
  • Laboratory diagnosis of Pneumocystis jirovecii in infants hospitalized with severe HIV-associated pneumonia
    Alfeu Passanduca | EDCTP2 project: EMPIRICAL
  • Cost and cost-effectiveness of scaling-up point-of-care very early infant diagnosis in Mozambique and Tanzania
    Kira Elsbernd | EDCTP2 project: LIFE
  • Comparative Analysis of Antibody Responses to CN54gp140 and AIDSVAX B/E in the PrEPVacc Trial
    Jennifer Serwanga | EDCTP2 project: PrEPVacc
  • I am not sick now, why should I swallow daily pills”:  non-uptake of and adherence to daily oral pre-exposure prophylaxis among adults at high risk of HIV in Masaka, Uganda
    Rachel Kawuma | EDCTP2 project: PrEPVacc
  • Disclosing Participation in an HIV Vaccine and PrEP Trial in Southwestern Uganda – the effect on participant engagement
    Sarah Nakamanya | EDCTP2 project: PrEPVacc
  • Knowledge and experiences of participating in an HIV vaccine efficacy trial  with second randomization to oral pre-exposure prophylaxis in South Africa, Tanzania, and Uganda
    Rachel Kawuma | EDCTP2 project: PrEPVacc
  • HIV incidence remains relatively high among women despite the availability of effective interventions
    Sylvia Kusemererwa | EDCTP2 project: PrEPVacc
  • HIV risk perception, trust and PrEP adherence among participants in an HIV prevention trial:  a qualitative longitudinal study, South Africa
    Rujeko Samanthia Chimukuche | EDCTP2 project: PrEPVacc
  • High prevalence of transmitted and acquired drug resistance mutations among newly HIV diagnosed neonates and infants from Mozambique
    Nuno Taveria | EDCTP2 project: LIFE
  • Acceptability of point-of-care viral load monitoring among children and young people living with HIV in East Africa: a qualitative study
    I. Marion Sumari-de Boer | EDCTP2 project: EAPOC

e-Poster presentations

  • WRITTEN ON THE SKIN: Participants’ perspectives on scarring, discolouration and implant site reactions experienced during a Phase I clinical trial for a subdermal HIV prevention implant in South Africa
    EDCTP2 project: CAPRISA 018
  • Designing a complex intervention to increase neonatal HIV test-and-treat and maximize the long-term impact on infant health (LIFE2Scale)
    Arne Kroidl | EDCTP2 project: LIFE2Scale

Poster walk

  • Cost and cost-effectiveness of scaling-up point-of-care very early infant diagnosis in Mozambique and Tanzania
    Kira Elsbernd | EDCTP2 project: LIFE

International Workshop on Pediatrics & HIV

  • High prevalence of transmitted and acquired drug resistance mutations among newly HIV diagnosed neonates and infants from Mozambique
    Arne Kroidl | EDCTP2 project: LIFE
    19 July 2024 | 10:45-12:15
  • Causes of Death Among Infants Living With HIV and Hospitalized With Severe Pneumonia in Sub-Saharan African Countries: Preliminary Results From the EMPIRICAL Trial
    Lola Madrid | EDCTP2 project: EMPIRICAL
    19 July 2024 | 13:40-15:15

HIV portofolio

Here is an overview of EDCTP2- and Global Health EDCTP3-funded studies on HIV and HIV-associated infections, some of which may also present their work at AIDS 2024.

EDCTP2-funded projects in the area of HIV